Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes

This study published in PNAS elucidated the mechanism by which the anticancer peptide PNC-27 selectively kills tumor cells. PNC-27 is a chimeric peptide containing an HDM-2-binding domain (human homolog of the MDM-2 protein) fused with a membrane leader domain, designed to exploit molecular differences between normal and cancer cells.

The main discovery was that PNC-27 kills cancer cells through membranolysis — the physical disruption of the cell membrane. The mechanism is highly specific: the HDM-2 protein is present on the plasma membranes of tumor cells but absent from the membranes of normal cells (where it is located in the cytoplasm/nucleus). This differential distribution allows PNC-27 to selectively bind to tumor membranes.

The researchers demonstrated using circular dichroism and nuclear magnetic resonance techniques that:

• PNC-27 adopts an amphipathic alpha-helical conformation required for HDM-2 binding
• Binding to membrane HDM-2 creates pores in the tumor membrane, leading to cell lysis
• Normal cells were not affected by the treatment, confirming selectivity

The selective cytotoxicity was confirmed across multiple tumor cell lines, including pancreatic cancer, breast cancer, and melanoma. The time to induce cell death was a few hours, indicating a rapid and direct mechanism of action. This work was fundamental in validating the concept that aberrant protein localization in cancer cells can be therapeutically exploited, opening new perspectives for the development of selective anticancer peptides.